Toleranzia announces continued promising results in the production of TOL2

24 August - 2021

Toleranzia AB ("Toleranzia" or the "Company") has conducted so called “consistency batches” at the contract manufacturer 3P Biopharmaceuticals (3P), which involves the production of two independent TOL2 purification batches to verify that the results are reproducible and that the final product is of the same high quality in both batches. The company notes that the purification process continues to develop well and although some adjustments to the process remain to be implemented, the results encouragingly show that the yield of pure TOL2 has further improved significantly. In the now developed purification batches, the amount of TOL2 obtained has doubled. A high yield of TOL2 is essential to achieve the best possible production economy, and therefore any improvement in the manufacturing process is highly valuable.

CEO Charlotte Fribert comments:
– We continue to see increased productivity in the TOL2 production process as 3P continues to increase yields in both the cultivation and purification parts of the process. This is very promising and provides sustained support for the completion of the GMP 1000 L scale TOL2 manufacturing process for the TOL2 human clinical trial on schedule.

For further information, please contact:
Charlotte Fribert – CEO, Toleranzia
Telephone: +46 763 19 98 98

About Toleranzia AB (publ)
Toleranzia AB (556877-2866) is a Swedish biotechnology company listed on Nasdaq First North Growth Market. The company develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can alleviate or cure the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's main focus is the autoimmune nerve and muscle disease myasthenia gravis (MG), for which it is developing the drug candidate TOL2. In addition, Toleranzia is working on the autoimmune blood vessel disease ANCA-vasculitis, for which it is developing the drug candidate TOL3. Both diseases are so-called orphan diseases, and both have a high unmet medical need and market potential. Toleranzia was founded by researchers at the University of Gothenburg. The company is based at the Biotech Center in Gothenburg. For further information, please visit:

Subscribe to Toleranzia’s news here